Hetero entered into the development of Biosimilar products in 2009. Our capabilities in R&D have once again come to the fore with the launch of several biosimilar products – Darbepoetin alfa, Rituximab, Bevacizumab and in India within 5 years of initiation.
When it comes to Biosimilars, we have the advantage of single site state-of-the-art manufacturing and R & D and adherence to global standards. With few more pipeline products close to actualization we are confident of introducing more biosimilar products in the future.
Hetero has the distinction of bringing 3 biosimilar products to market within 5 years of inception. This has placed us amongst the select biotech companies with the capability to develop, manufacture and commercialize complex monoclonal antibodies (mAbs).